CenterBook Partners LP Has $2.44 Million Stake in Indivior PLC $INDV

CenterBook Partners LP lowered its position in Indivior PLC (NASDAQ:INDV) by 37.8% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 68,079 shares of the company’s stock after selling 41,380 shares during the period. CenterBook Partners LP owned 0.05% of Indivior worth $2,443,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Goldman Sachs Group Inc. lifted its stake in Indivior by 18.4% in the first quarter. Goldman Sachs Group Inc. now owns 8,368,996 shares of the company’s stock valued at $79,757,000 after buying an additional 1,299,425 shares during the period. Jane Street Group LLC raised its position in Indivior by 2,597.9% in the 1st quarter. Jane Street Group LLC now owns 995,013 shares of the company’s stock valued at $9,327,000 after buying an additional 958,132 shares during the last quarter. JPMorgan Chase & Co. raised its position in Indivior by 669.1% in the 2nd quarter. JPMorgan Chase & Co. now owns 391,386 shares of the company’s stock valued at $5,769,000 after buying an additional 340,498 shares during the last quarter. Prudential Financial Inc. purchased a new stake in Indivior in the 2nd quarter valued at $207,000. Finally, Walleye Capital LLC purchased a new stake in Indivior in the 2nd quarter valued at $594,000. Institutional investors and hedge funds own 60.33% of the company’s stock.

Indivior Price Performance

Shares of NASDAQ:INDV opened at $38.26 on Wednesday. The company has a market capitalization of $4.66 billion, a PE ratio of 19.62 and a beta of 0.88. The business has a fifty day moving average price of $34.94 and a two-hundred day moving average price of $34.19. Indivior PLC has a 1 year low of $13.44 and a 1 year high of $41.00.

Indivior (NASDAQ:INDV) last announced its quarterly earnings data on Tuesday, March 31st. The company reported $0.96 earnings per share (EPS) for the quarter. The firm had revenue of $317.00 million during the quarter. Indivior had a negative return on equity of 219.26% and a net margin of 19.44%. Sell-side analysts anticipate that Indivior PLC will post 4.05 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on INDV shares. Weiss Ratings lowered Indivior from a “hold (c+)” rating to a “hold (c)” rating in a research report on Wednesday, May 6th. Zacks Research raised Indivior from a “hold” rating to a “strong-buy” rating in a research report on Monday, March 16th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, Indivior has a consensus rating of “Buy” and a consensus target price of $39.33.

Indivior Company Profile

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.